1. Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study
   Xiao-Xu Zhu et al, 2023, BMC Cancer CrossRef
2. Telmisartan-Induced Cytotoxicity via G₂/M Phase Arrest in Renal Cell Carcinoma Cell Lines
   Yoshie Tsujiya et al, 2021, Biological and Pharmaceutical Bulletin CrossRef
3. Drug Repurposing in Gastric Cancer: Current Status and Future Perspectives
   Marina Leite et al, 2023, Hereditary Gastric and Breast Cancer Syndrome CrossRef
4. Interaction of telmisartan and related sartans with the programmed cell death-ligand 1 (PD-L1) protein dimer: a molecular docking analysis
   Gérard Vergoten et al, 2023, Future Journal of Pharmaceutical Sciences CrossRef
5. IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway
   Mi-Ae Kang et al, 2021, Journal of Personalized Medicine CrossRef
6. Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort
   Somayye Taghvaei et al, 2021, Frontiers in Pharmacology CrossRef
7. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis
   Wenkai Jiang et al, 2022, Expert Review of Gastroenterology & Hepatology CrossRef
8. The potential anticancer activities of telmisartan – a literature review
   Andriana Hadjiyianni et al, 2023, Annales Academiae Medicae Silesiensis CrossRef
9. Repurposed Drugs in Gastric Cancer
   Diana Araújo et al, 2022, Molecules CrossRef
10. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
    Richard E. Kast et al, 2022, Cancers CrossRef